Odronextamab Recommended for EU Approval by the CHMP to Treat R/R Follicular Lymphoma and DLBCL July 1, 2024
Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with R/R Follicular Lymphoma July 1, 2024
FDA issued CRLs for the BLAs for odronextamab in R/R follicular lymphoma (FL) and in R/R DLBCL, each after two or more lines of systemic therapy March 26, 2024
Mosunetuzumab Achieved Primary Endpoint in Expansion Cohort of Japanese Ph 1 study for R/R Follicular Lymphoma March 18, 2024
FDA Accepts for Priority Review the Supplemental BLA for Epcoritamab (EPKINLY®) for Difficult-to-Treat R/R Follicular Lymphoma March 4, 2024
Regulatory Applications Accepted in the U.S. and Japan for Breyanzi (lisocabtagene maraleucel) in R/R Follicular Lymphoma and R/R Mantle Cell Lymphoma February 26, 2024
FDA granted BTD and EMA application validated for Epcoritamab (EPKINLY®/TEPKINLY®) for the Treatment of R/R Follicular Lymphoma December 4, 2023
European Commission Approves BRUKINSA® (zanubrutinib) for the Treatment of R/R Follicular Lymphoma November 29, 2023
Odronextamab BLA for Treatment of R/R Follicular Lymphoma (FL) and DLBCL Accepted for FDA Priority Review October 3, 2023
Supplemental NDA submitted to FDA for BRUKINSA + obinutuzumab in R/R follicular lymphoma July 19, 2023
Positive Topline Results from Ph 1/2 EPCORE™ NHL-1 Trial of Epcoritamab in Patients with R/R Follicular Lymphoma announced July 5, 2023
ICML 2023: Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in R/R FL and MCL in TRANSCEND Clinical Trials June 28, 2023
TRANSCEND FL and TRANSCEND NHL 001 Studies of Breyanzi in R/R FL and MCL Meet Primary Endpoint of ORR May 10, 2023
FDA approved Lunsumio® (mosunetuzumab-axgb) for the treatment of adult patients with R/R follicular lymphoma January 4, 2023
FDA approves Kymriah® CAR-T cell therapy for adult patients with R/R follicular lymphoma June 13, 2022
